4Q 18 Earnings Call Presentation. August 28, 2018
|
|
- Dwain Pierce
- 5 years ago
- Views:
Transcription
1 4Q 18 Earnings Call Presentation August 28, 2018
2 Agenda John Chiminski, Chair & Chief Executive Officer 4Q 18 Highlights Wetteny Joseph, Senior VP & Chief Financial Officer Segment Reporting Structure Changes Business Update by Segment 4Q 18 and YTD Segment Financial Performance EBITDA & Adjusted EBITDA Adjusted Net Income and Adjusted Net Income per Share Capitalization Highlights FY 19 Financial Guidance Question & Answer Session 2
3 Disclaimer Statement Forward-Looking Statements This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as believe, expect, anticipate, intend, estimate, plan, project, foresee, likely, may, will, would or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; and our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs; or difficulty in integrating acquisitions into our existing business, thereby reducing or eliminating the anticipated benefits of the acquisition. For a more detailed discussion of these and other factors, see the information under the caption Risk Factors in our Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the Securities and Exchange Commission. All forward-looking statements in this presentation speak only as of the date of this presentation or as of the date they are made, and we do not undertake to update any forward-looking statement as a result of new information or future events or developments unless and to the extent required by law. Non-GAAP Financial Measures Management measures operating performance based on consolidated earnings from continuing operations before interest expense, expense/ (benefit) for income taxes and depreciation and amortization and is adjusted for the income or loss attributable to non-controlling interest ( EBITDA from continuing operations ). EBITDA from continuing operations is not defined under U.S. GAAP and is not a measure of operating income, operating performance or liquidity presented in accordance with U.S. GAAP and is subject to important limitations. Management believes these non-gaap financial measures provide useful supplemental information for its investors evaluation of the Company s business performance and are useful for period-over-period comparisons of the performance of the Company s business. 3
4 Disclaimer Statement - Continued We believe that the presentation of EBITDA from continuing operations enhances an investor s understanding of our financial performance. We believe this measure is a useful financial metric to assess our operating performance from period to period by excluding certain items that we believe are not representative of our core business and we use this measure for business planning purposes. In addition, given the significant investments that we have made in the past in property, plant and equipment, depreciation and amortization expenses represent a meaningful portion of our cost structure. We believe that EBITDA from continuing operations will provide investors with a useful tool for assessing the comparability between periods of our ability to generate cash from operations sufficient to pay taxes, to service debt and to undertake capital expenditures because it eliminates depreciation and amortization expense. We present EBITDA from continuing operations in order to provide supplemental information that we consider relevant for the readers of our financial statements, and such information is not meant to replace or supersede U.S. GAAP measures. Our definition of EBITDA from continuing operations may not be the same as similarly titled measures used by other companies. As changes in exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a constant currency basis in addition to reported results helps improve investors ability to understand our operating results and evaluate our performance in comparison to prior periods. Constant currency information compares results between periods, as if exchange rates had remained constant period-over-period. We use results on a constant currency basis as one measure to evaluate our performance. In this release, we calculate constant currency by calculating current-year results using prior-year foreign currency exchange rates. We generally refer to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange translation. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP. In addition, the Company evaluates the performance of its segments based on segment earnings before non-controlling interest, other (income) expense, impairments, restructuring costs, interest expense, income tax (benefit)/expense, and depreciation and amortization ( Segment EBITDA ). Under our credit agreement, our ability to engage in certain activities such as incurring certain additional indebtedness, making certain investments and paying certain dividends is tied to ratios based on Adjusted EBITDA (which is defined as Consolidated EBITDA in the credit agreement). Adjusted EBITDA is based on the definitions in the our credit agreement, is not defined under U.S. GAAP, and is subject to important limitations. We have included the calculations of Adjusted EBITDA for the periods presented. Adjusted EBITDA is the covenant compliance measure used in certain covenants under our credit agreement, particularly those governing debt incurrence and restricted payments. Because not all companies use identical calculations, our presentation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies. 4
5 Disclaimer Statement - Continued Management also measures operating performance based on Adjusted Net Income/(loss) and Adjusted Net Income per Share. Adjusted Net Income/(loss) is not defined under U.S. GAAP and is not a measure of operating income, operating performance or liquidity presented in accordance with U.S. GAAP and is subject to important limitations. For example, Adjusted Net Income does not reflect the impact on earnings resulting from certain non-recurring items. We believe that the presentation of Adjusted Net Income/(loss) and Adjusted Net Income per Share enhances an investor s understanding of our financial performance. We believe this measure is a useful financial metric to assess our operating performance from period to period by excluding certain items that we believe are not representative of our core business and we use this measure for business planning purposes. We define Adjusted Net Income/(loss) as net earnings/(loss) adjusted for (1) earnings or loss of discontinued operations, net of tax, (2) amortization attributable to purchase accounting and (3) income or loss from non-controlling interest in our majority-owned operations. We also make adjustments for other cash and non-cash items, partially offset by our estimate of the tax effect as a result of such cash and non-cash items. We believe that Adjusted Net Income/(loss) and Adjusted Net Income per Share will provide investors with a useful tool for assessing the comparability between periods of our ability to generate cash from operations available to our stockholders. We present Adjusted Net Income/(loss) and Adjusted Net Income per Share in order to provide supplemental information that we consider relevant for the readers of our financial statements and such information is not meant to replace or supersede U.S. GAAP measures. Our definition of Adjusted Net Income/(loss) may not be the same as similarly titled measures used by other companies. The Company does not provide a reconciliation of forward-looking non-gaap financial measures to their comparable GAAP financial measures because it could not do so without unreasonable effort due to the unavailability of the information needed to calculate reconciling items and due to the variability, complexity and limited visibility of the adjusting items that would be excluded from the non-gaap financial measures in future periods. When planning, forecasting and analyzing future periods, the Company does so primarily on a non-gaap basis without preparing a GAAP analysis as that would require estimates for various cash and non-cash reconciling items that would be difficult to predict with reasonable accuracy. For example, equity compensation expense would be difficult to estimate because it depends on the company s future hiring and retention needs, as well as the future fair market value of the company s common stock, all of which are difficult to predict and subject to constant change. It is equally difficult to anticipate the need for or magnitude of a presently unforeseen one-time restructuring expense or the values of end-of-period foreign currency exchange rates. As a result, the Company does not believe that a GAAP reconciliation would provide meaningful supplemental information about the Company s outlook. 5
6 Business Highlights Financial Highlights 4Q 18 revenue of $685.3M, up 11% vs. PY as reported, 9% in constant currency Full year 18 revenue up 19% vs. PY as reported, 16% in constant currency Strong 4Q 18 and full-year revenue and EBITDA growth driven by Biologics and Specialty Drug Delivery and Clinical Supply Services segments 4Q 18 Adjusted EBITDA of $181.5M, 11% growth vs. PY in constant currency 4Q 18 Adjusted Net Income of $90.0M; Adjusted EPS of $0.67 per diluted share Operational Highlights Closed the acquisition of Juniper Pharmaceuticals, a European early development Center of Excellence with dose-form development and early manufacturing capabilities Issued 11.4M shares of common stock at a price to the public of $40.24 and used the net proceeds ($445M) plus cash on hand to pay down $450M of floating rate debt; pro forma net leverage ratio reduced to 3.4x Organic and inorganic investments in our Biologics business continue to pay off; the integration of the Bloomington facility is very far advanced 6
7 Segment Reporting Structure Changes Catalent, Inc. (CTLT) Softgel Technologies Drug Delivery Solutions Clinical Supply Services FY 18 Net Revenue $917M FY 18 Net Revenue $1,176M FY 18 Net Revenue $430M Unchanged Split into Two Segments Unchanged Biologics and Specialty Drug Delivery FY 18 Net Revenue $602M Biologics: Drug Substance, GPEx Biologics: Drug Product Blow-Fill-Seal Inhalation Analytical Services (large molecule) Oral Drug Delivery FY 18 Net Revenue $574M Modified Release, Other oral solids Analytical Services (small molecule) Spray Dry Dispersion Micronization Former Juniper Pharmaceuticals SMARTag 7
8 Softgel Technologies 4Q 18 revenue and EBITDA below PY due to North America and Europe Decline in high-margin product participation revenue negatively affects segment EBITDA margin North American and European revenue and EBITDA below prior-year levels due to lower sales of consumer health and prescription products; Ibuprofen shortage impact Accucaps modestly below PY at revenue line, but strong EBITDA performance driven by product mix and operational efficiencies Increased demand across Latin America; favorable product mix in Asia Pacific following divestiture of lower margin businesses Three Months Ended As Reported Inc. / (Dec.) Constant Currency Inc. / (Dec.) (USD M) June 30, 2018 June 30, 2017 $ % $ % Softgel Technologies Net Revenue (16.1) (6%) (17.8) (7%) Segment EBITDA (6.2) (10%) (5.0) (8%) 8
9 Biologics and Specialty Drug Delivery 4Q 18 revenue up sharply, and EBITDA more than double the PY period Bloomington site continues its strong start, contributing 71 and 116 percentage points to the segment s revenue and EBITDA growth, respectively BSDD organic growth: revenue up 27%, Segment EBITDA up 35% Strong drug substance performance in Madison and drug product performance in Europe; Madison 3 rd suite continues to ramp up nicely BFS: comprehensive operating systems review largely complete; 4Q performance modestly above our expectations; strong growth vs. PY due to improved capacity utilization Three Months Ended As Reported Inc. / (Dec.) Constant Currency Inc. / (Dec.) (USD M) June 30, 2018 June 30, 2017 $ % $ % Biologics and Specialty Drug Delivery Net Revenue % % Segment EBITDA % % 9
10 Oral Drug Delivery Challenging 4Q 18 driven by contract settlement realized in the PY period Decline in product participation revenue continues and negatively affected Segment EBITDA and margin profile Prior-year results included a contractual settlement U.S. and Europe commercial: volume in-line with PY levels, unfavorable product mix negatively affected profitability; end-market demand remains robust Analytical services business modestly below PY levels, but improved from 3Q 18 performance Three Months Ended As Reported Inc. / (Dec.) Constant Currency Inc. / (Dec.) (USD M) June 30, 2018 June 30, 2017 $ % $ % Oral Drug Delivery Net Revenue (19.9) (11%) (23.9) (14%) Segment EBITDA (17.0) (25%) (18.4) (27%) 10
11 Clinical Supply Services 4Q 18 performance nicely above PY; revenue +5%, EBITDA +20% Revenue and Segment EBITDA growth across core storage and distribution services, globally; improved capacity utilization across the network continues Decreased lower-margin comparator sourcing volumes during the quarter; minimal impact on segment profitability Backlog of $273M as of June 30, 2018 increased 2% from the prior quarter; LTM book-to-bill ratio of 0.9x; net new business wins of $93M increased 60% vs. the prior year period; backlog and ratio figures adjusted for ASC 606 revenue recognition change related to treatment of comparator revenue Three Months Ended As Reported Inc. / (Dec.) Constant Currency Inc. / (Dec.) (USD M) June 30, 2018 June 30, 2017 $ % $ % Clinical Supply Services Net Revenue % 4.9 5% Segment EBITDA % % 11
12 4Q 18 by Business Segment 12
13 Full Year 2018 by Business Segment 13
14 Operating Earnings to EBITDA 14
15 EBITDA Adjustments 15
16 Summary Adjusted Net Income and ANI per Share 16
17 Capitalization and Capital Allocation Capitalization Term loan covenant-light structure provides attractive cost of capital and maturity profile (1) (2) No significant maturities until 2024 Reduced TL spread as part of 2Q 18 debt issuance: USD 50 bps and EUR 75 bps Paid down $450M of USD TL in July 18 with equity proceeds and cash; annual interest rate savings of $20M+ 380M, 4.75% EUR 8-yr notes issued in 2Q 17 $450M, 4.875% USD 8-yr notes issued in 2Q 18; proceeds used in Cook acquisition Capital Allocation Capital expenditures of ~7% of revenues Ongoing capital allocation will be focused on: Capex to drive organic growth M&A to supplement organic growth Share repurchase or debt reduction Strong free cash flow generation in FY 18: ~$200 million; ~86% of Adj. Net Income Total net leverage ratio of 4.2x, but 3.4x pro forma for the Cook and Juniper acquisitions and the $450M paydown of USD term loan 17
18 FY 19 Full-Year Guidance Notes: (1) FY 18 capital expenditures include customer-funded projects; FY 19 guidance is only Catalent spend (2) Share count is fully diluted and represents the weighted average as of June 30 Revenue, Adjusted EBITDA, Adjusted Net Income guidance ranges calculated based on: 1.30 USD/GBP, 1.16 USD/EUR No fundamental change to long-term outlook: organic revenue growth of 4-6%, organic Adjusted EBITDA growth of 6-8%; however, FY 19 Adjusted EBITDA guidance reflects stronger growth (7-9%) 18
19 FY 19 Guidance Bridge Revenue Adj. EBITDA (USD M) Base Business Organic Growth M&A ASC 606 FX Impact $95-$145 $100 $115 ($110) ($40) ($50) $2,500-$2,590 $2,463 $28-$38 ($13)-($18) $38-$52 $597-$622 $551 Guidance midpoint: 160 bps of margin expansion FY 18 Actuals FY 19 Guidance Base Business: Revenue $95M-$145M, Adjusted EBITDA $38M-$52M represents organic, same-store revenue and adjusted EBITDA growth across the business on a constant-currency basis; aligns with our longterm outlook of 4-6% revenue growth, but above our long-term outlook of adjusted EBITDA (guidance supports 7-9% vs. target of 6-8%) M&A: Revenue $100M-$115M, Adjusted EBITDA $28M-$38M adjustment for full-year impact of Bloomington acquisition completed in 2Q 18, as well as contribution from recently closed Juniper Pharmaceuticals (1Q 19) ASC 606 Revenue Recognition: Revenue ($110M), no Adjusted EBITDA impact related to removal of gross comparator revenue from CSS segment in FY 19; no impact to other reporting segments FX impact: Revenue ($40M)-($50M), Adjusted EBITDA ($13M)-($18M) recent USD strengthening vs. EUR and GBP; guidance assumes EUR 1.16 and GBP 1.30, down from FY 18 average rates of EUR 1.19 and GBP 1.35; further weakening of ARS and BRL (Latin America Softgel) also contributes 19
20 Supplemental Information 20
21 Detailed Adjusted Net Income and ANI per Share 21
22 Reconciliation of Actual to Adjusted Results 22
23 Quarterly Revenue and EBITDA by New Reporting Segment; FY 17 and FY 18 23
24 discover more. CATALENT, INC. 14 SCHOOLHOUSE ROAD SOMERSET, NJ
2Q 19 Earnings Call Presentation. February 5, 2019
2Q 19 Earnings Call Presentation February 5, 2019 Agenda John Chiminski, Chair & Chief Executive Officer 2Q 19 Highlights Wetteny Joseph, Senior VP & Chief Financial Officer Business Update by Segment
More information2Q 18 Earnings Call Presentation. February 5, 2018
2Q 18 Earnings Call Presentation February 5, 2018 Agenda John Chiminski, Chairman & Chief Executive Officer 2Q 18 Highlights Matt Walsh, Executive VP & Chief Financial Officer Business Update by Segment
More information4Q 16 Earnings Call Presentation. August 29, 2016
4Q 16 Earnings Call Presentation August 29, 2016 Agenda John Chiminski, President & Chief Executive Officer 4Q 16 Highlights Matt Walsh, Executive VP & Chief Financial Officer Business Update by Segment
More information36 th Annual J.P. Morgan Healthcare Conference. January 8, 2018
36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements other than statements
More informationFY 14 Q2 Earnings Presentation MATTHEW WALSH EVP & CFO
FY 14 Q2 Earnings Presentation MATTHEW WALSH EVP & CFO 02.10.14 Disclaimer Statement Forward Looking Statements This presentation and release contains both historical and forward-looking statements. All
More informationCatalent to Acquire Cook Pharmica. September 19, 2017
Catalent to Acquire Cook Pharmica September 19, 2017 Disclaimer Statement Forward-Looking Statements This release contains both historical and forward-looking statements, including concerning the closing
More information31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO
31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO 01.08.2013 Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements
More informationGoldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO
Goldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO 05.01.2012 Forward Looking Statements This presentation contains both historical and forward-looking statements.
More informationBank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO
Bank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements other than
More informationCATALENT PHARMA SOLUTIONS, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationCatalent, Inc. Jefferies Global Healthcare Conference. June 9, DEVELOPMENT DELIVERY SUPPLY more products. better treatments. reliably supplied.
Catalent, Inc. Jefferies Global Healthcare Conference June 9, 2016 DEVELOPMENT DELIVERY SUPPLY more products. better treatments. reliably supplied. Disclaimer Statement Forward-Looking Statements This
More informationCatalent, Inc. Raymond James Institutional Investors Conference. March 7, 2016
Catalent, Inc. Raymond James Institutional Investors Conference March 7, 2016 Disclaimer Statement Forward-Looking Statements This press release contains both historical and forward-looking statements.
More informationCATALENT PHARMA SOLUTIONS, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationXYLEM INC. Q EARNINGS RELEASE FEBRUARY 1, 2018
XYLEM INC. Q4 2017 EARNINGS RELEASE FEBRUARY 1, 2018 Q4 2017 EARNINGS RELEASE FORWARD-LOOKING STATEMENTS This presentation contains information that may constitute forward-looking statements. Forward-looking
More informationZebra Technologies Third-Quarter 2018 Results. November 6, 2018
Zebra Technologies Third-Quarter 2018 Results November 6, 2018 1 Safe Harbor Statement Statements made in this presentation which are not statements of historical fact are forward-looking statements and
More informationCatalent, Inc. $400,000,000. Common stock. J.P. Morgan Morgan Stanley RBC Capital Markets BofA Merrill Lynch Wells Fargo Securities
The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are
More informationFirst Quarter 2018 Earnings Call Chip Blankenship Chief Executive Officer Ken Giacobbe Chief Financial Officer
First Quarter 2018 Earnings Call Chip Blankenship Chief Executive Officer Ken Giacobbe Chief Financial Officer April 30, 2018 Important Information Forward Looking Statements This presentation contains
More informationXYLEM INC. Q EARNINGS RELEASE OCTOBER 30, 2018
XYLEM INC. Q3 2018 EARNINGS RELEASE OCTOBER 30, 2018 Q3 2018 EARNINGS RELEASE FORWARD-LOOKING STATEMENTS This presentation contains information that may constitute forward-looking statements. within the
More informationXYLEM INC. Q EARNINGS RELEASE MAY 1, 2018
XYLEM INC. Q1 2018 EARNINGS RELEASE MAY 1, 2018 Q1 2018 EARNINGS RELEASE FORWARD-LOOKING STATEMENTS This presentation contains information that may constitute forward-looking statements. Forward-looking
More informationCatalent, Inc. 34 th Annual J.P. Morgan Healthcare Conference. John Chiminski President & CEO January 11, 2016
Catalent, Inc. 34 th Annual J.P. Morgan Healthcare Conference John Chiminski President & CEO January 11, 2016 Disclaimer Statement Forward-Looking Statements This press release contains both historical
More informationFebruary 14, Q Earnings Presentation
February 14, 2019 Q4 2018 Earnings Presentation Certain statements contained in this presentation that are not historical facts, including any statements as to future market conditions, results of operations,
More informationZebra Technologies Second-Quarter 2018 Results. August 7, 2018
Zebra Technologies Second-Quarter 2018 Results August 7, 2018 Safe Harbor Statement Statements made in this presentation which are not statements of historical fact are forward-looking statements and are
More informationXYLEM INC. Q EARNINGS RELEASE JULY 31, 2018
XYLEM INC. Q2 2018 EARNINGS RELEASE JULY 31, 2018 Q2 2018 EARNINGS RELEASE FORWARD-LOOKING STATEMENTS This presentation contains information that may constitute forward-looking statements. within the meaning
More informationSecond Quarter 2018 Results July 31, 2018
Second Quarter 2018 Results July 31, 2018 Eddie Edwards President and Chief Executive Officer Alex Pease Executive Vice President and Chief Financial Officer Safe harbor Caution Regarding Forward Looking
More information2Q 2017 Highlights and Operating Results
2Q 2017 Highlights and Operating Results July 25, 2017 1 2Q 2017 Highlights and Operating Results Table of Contents Page(s) 1 Sales Overview and Highlights 4-5 2 NSS Overview 6-7 3 EES Overview 8-9 4 UPS
More informationNovember 1, Q Earnings Presentation
November 1, 2018 Q3 2018 Earnings Presentation Certain statements contained in this presentation that are not historical facts, including any statements as to future market conditions, results of operations,
More informationSafe Harbor. Non-GAAP Financial Information
1 Safe Harbor This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including financial projections subject to risks, uncertainties
More informationAlbemarle Corporation Second Quarter 2018 Earnings and Non-GAAP Reconciliations Conference Call/Webcast Wednesday, August 8 th, :00am ET
Albemarle Corporation Second Quarter 2018 Earnings and Non-GAAP Reconciliations Conference Call/Webcast Wednesday, August 8 th, 2018 9:00am ET Forward-Looking Statements Some of the information presented
More informationCatalent Pharma Solutions Investor Overview
Catalent Pharma Solutions Investor Overview John Chiminski President & CEO January 10, 2011 more products. better treatments. reliably supplied. Disclaimer Statement Forward Looking Statements This presentation
More informationQ Financial Results. February 26, 2018
Q4 2017 Financial Results February 26, 2018 Forward Looking Statements & Non-GAAP Financial Measures Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationQ Conference Call. November 2, 2018
Q3 2018 Conference Call November 2, 2018 Forward Looking Statements This presentation contains forward-looking information regarding future events or the Company s future financial performance based on
More informationSafe Harbor Statement
Safe Harbor Statement Statements made in this presentation which are not statements of historical fact are forward-looking statements and are subject to the safe harbor provisions created by the Private
More informationQ Conference Call. August 2, 2017
Q2 2017 Conference Call August 2, 2017 Forward Looking Statements This presentation contains forward-looking information regarding future events or the Company s future financial performance based on the
More informationCATALENT PHARMA SOLUTIONS, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationACI WORLDWIDE QUARTERLY AND FULL-YEAR EARNINGS PRESENTATION
ACI WORLDWIDE QUARTERLY AND FULL-YEAR EARNINGS PRESENTATION Private Securities Litigation Reform Act of 1995 Safe Harbor For Forward-Looking Statements This presentation contains forward-looking statements
More informationFirst Quarter 2018 May 3, 2018
First Quarter 2018 May 3, 2018 Safe Harbor Please note that in this presentation, we may discuss events or results that have not yet occurred or been realized, commonly referred to as forward-looking statements.
More informationFourth Quarter 2016 Results
Fourth Quarter 2016 Results February 23, 2017 Eddie Edwards President and Chief Executive Officer Mark Olson Executive Vice President and Chief Financial Officer 1 Safe Harbor Caution Regarding Forward
More informationAugust 8, Conduent Q Earnings Results
August 8, 2018 Conduent Q2 2018 Earnings Results Cautionary Statements Forward-Looking Statements This report contains forward-looking statements, as defined in the Private Securities Litigation Reform
More information~400 SIGNIFICANT CLIENTS ~700 PRODUCTS 70+ COUNTRIES 75% OF ALL DOSAGE FORMS 21% ALL OUTSOURCED FDA APPROVALS IN LAST DECADE 95%+ RFT/OTD
~400 SIGNIFICANT CLIENTS ~700 PRODUCTS 70+ COUNTRIES JP Morgan Healthcare Conference Click to edit Master title style San Francisco, CA Click to edit July Master 11, 2016 text January 9, 2016 styles 75%
More informationFY 2017 Third Quarter Earnings Call
FY 2017 Third Quarter Earnings Call July 27, 2017 Improving the experience of a world in motion Forward Looking Statement Adient has made statements in this document that are forward-looking and, therefore,
More informationFiscal 2018 Third Quarter Results. 28 June 2018
Fiscal 2018 Third Quarter Results 28 June 2018 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are not
More informationFirst Quarter 2019 Earnings Presentation February 6, 2019
First Quarter 2019 Earnings Presentation February 6, 2019 Cautionary statements This presentation contains forward-looking statements that are subject to known and unknown risks and uncertainties, many
More informationThird Quarter 2018 Results November 8, 2018
Third Quarter 2018 Results November 8, 2018 Safe Harbor Caution Regarding Forward Looking Statements This presentation any other oral or written statements made by us or on our behalf may include forward-looking
More information4 TH QUARTER AND FULL YEAR 2015 RESULTS FEBRUARY 11, :00AM ET NYSE: NLSN
4 TH QUARTER AND FULL YEAR 2015 RESULTS FEBRUARY 11, 2016 8:00AM ET NYSE: NLSN SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS The following discussion contains forward-looking statements, including those about
More informationForward Looking Statements
Forward Looking Statements This presentation, as well as other statements made by Aptiv PLC (the Company ), contain forward-looking statements that reflect, when made, the Company s current views with
More informationFOURTH QUARTER & FULL YEAR 2018 EARNINGS CONFERENCE CALL. February 13, 2019
FOURTH QUARTER & FULL YEAR 2018 EARNINGS CONFERENCE CALL February 13, 2019 Overview Fourth quarter 2018 net revenue increased 13.3% o Organic growth of net revenue was 7.1% US organic growth was 6.3% International
More informationQuarterly Update FY17 Fourth Quarter. November 9, 2017
Quarterly Update FY17 Fourth Quarter November 9, 2017 1 Johnson Controls plc. November 9, 2017 Johnson Controls International plc Cautionary Statement Regarding Forward-Looking Statements Johnson Controls
More informationQ3 FY17 Results August 3, 2017
Q3 FY17 Results August 3, 2017 Steve Voorhees Chief Executive Officer Ward Dickson Chief Financial Officer Jim Porter President, Business Development and Latin America Jeff Chalovich President, Corrugated
More informationFourth Quarter 2018 Earnings Call John Plant Chairman and Chief Executive Officer Ken Giacobbe Chief Financial Officer
Fourth Quarter 2018 Earnings Call John Plant Chairman and Chief Executive Officer Ken Giacobbe Chief Financial Officer February 8, 2019 Important Information Forward Looking Statements This presentation
More informationA X A L T A C O A T I N G S Y S T E M S. Q FINANCIAL RESULTS July 26, 2016
A X A L T A C O A T I N G S Y S T E M S Q2 2016 FINANCIAL RESULTS July 26, 2016 Legal Notices Forward-Looking Statements This presentation and the oral remarks made in connection herewith may contain forward-looking
More informationSecond Quarter 2018 Earnings Presentation May 8, 2018
Second Quarter 2018 Earnings Presentation May 8, 2018 Cautionary statements This presentation contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of
More informationQ Earnings Call. November 5, 2012
Q4 2012 Earnings Call November 5, 2012 Forward-Looking Statements and Non-GAAP Measures Forward-Looking Statements -- This presentation contains certain forward-looking statements within the meaning of
More informationBank of America Merrill Lynch 2017 Global Agriculture Conference
Bank of America Merrill Lynch 2017 Global Agriculture Conference March 1, 2017 Safe Harbor Please note that in this presentation, we may discuss events or results that have not yet occurred or been realized,
More informationFirst Quarter 2017 Results & Outlook for May 2, 2017
First Quarter 2017 Results & Outlook for 2017 May 2, 2017 Forward-Looking Statements and Risk Factors This presentation contains statements which constitute forward-looking statements, within the meaning
More informationVISTEON CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in Millions, Except Per Share Data) (Unaudited)
CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in Millions, Except Per Share Data) (Unaudited) Three Months Ended Six Months Ended June 30 June 30 2018 2017 2018 2017 Sales $ 758 $ 774 $ 1,572 $ 1,584
More informationThird Quarter 2018 Earnings Call
Third Quarter 2018 Earnings Call October 25, 2018 Nick Zarcone President & Chief Executive Officer Varun Laroyia Executive Vice President & Chief Financial Officer Joe Boutross Vice President, Investor
More information1Q 2018 Highlights and Operating Results
1Q 2018 Highlights and Operating Results April 26, 2018 1 Table of Contents Page(s) 4 Announced Agreements to Acquire Australia and New Zealand Security Businesses 5-9 Sales Overview 10-17 Financial Performance
More informationQ2 FY17 Results April 26, 2017
Q2 FY17 Results April 26, 2017 Steve Voorhees Chief Executive Officer Ward Dickson Chief Financial Officer Jim Porter President, Business Development and Latin America Jeff Chalovich President, Corrugated
More informationEARNINGS PRESENTATION
EARNINGS PRESENTATION Fourth Quarter & Full Year 2017 Aleris Corporation March 19, 2018 Forward-Looking and Other Information IMPORTANT INFORMATION This information is current only as of its date and may
More informationMSCI THIRD QUARTER 2016
MSCI THIRD QUARTER 2016 Earnings Presentation October 27, 2016 2016 MSCI Inc. All rights reserved. Please refer to the disclaimer at the end of this document. FORWARD-LOOKING STATEMENTS Forward-Looking
More informationA X A L T A C O A T I N G S Y S T E M S. Q FINANCIAL RESULTS October 27, 2016
A X A L T A C O A T I N G S Y S T E M S Q3 2016 FINANCIAL RESULTS October 27, 2016 Legal Notices Forward-Looking Statements This presentation and the oral remarks made in connection herewith may contain
More informationCrane Co. Q Earnings Release Call
Crane Co. Q4 2018 Earnings Release Call FORWARD-LOOKING STATEMENTS DISCLAIMER The information in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation
More informationQ EARNINGS CALL FEBRUARY 20, 2018
Q4 2017 EARNINGS CALL FEBRUARY 20, 2018 1 IMPORTANT INFORMATION Forward Looking Statements These slides contain (and the accompanying oral discussion will contain) forward looking statements. All statements
More information2018 FOURTH QUARTER EARNINGS CALL
NORTH AMERICA S LEADING BUILDING MATERIALS DISTRIBUTOR RESIDENTIAL COMMERCIAL INTERIOR SOLAR 2018 FOURTH QUARTER EARNINGS CALL Forward Looking Statements / Non-GAAP Measures This presentation contains
More informationPrincipal Financial Group 2016 Outlook Call
Principal Financial Group Call December 3, 2015 Use of Non-GAAP Financial Measures A non-gaap financial measure is a numerical measure of performance, financial position, or cash flows that includes adjustments
More informationFourth Quarter 2015 Earnings Call February 11, 2016
Fourth Quarter 205 Earnings Call February, 206 Copyright 206 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements within the
More informationQ Earnings. November 2, 2016
Q4 2016 Earnings November 2, 2016 Forward-Looking Statements and Non-GAAP Measures Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the U.S.
More informationHorizon Global Third Quarter 2017 Earnings Presentation
Horizon Global Third Quarter 2017 Earnings Presentation October 31, 2017 Q1 2016 Earnings 1 Safe Harbor Statement Forward-Looking Statements This presentation may contain "forward-looking statements" as
More informationFourth Quarter and Fiscal 2018 Results. October 11, 2018
Fourth Quarter and Fiscal 2018 Results October 11, 2018 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that
More informationFourth Quarter and Fiscal 2016 Results. 20 October 2016
Fourth Quarter and Fiscal 2016 Results 20 October 2016 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that
More informationRaymond James 37 th Annual Institutional Investors Conference. March 8, 2016
Raymond James 37 th Annual Institutional Investors Conference March 8, 2016 Forward-looking statements and Non-GAAP financial measures Forward-looking statements Certain statements included in this presentation,
More informationCatalent Pharma Solutions, Inc. and Subsidiaries and Predecessor. Consolidated and Combined Financial Statements
Catalent Pharma Solutions, Inc. and Subsidiaries and Predecessor Consolidated and Combined Financial Statements As of June 30, 2007 and 2006, For the periods April 10, 2007 to June 30, 2007, July 1, 2006
More informationCushman & Wakefield. Q2 Earnings Presentation September 5, 2018
Cushman & Wakefield Q2 Earnings Presentation September 5, 2018 Cautionary Note on Forward-Looking Statements All statements in this presentation (and oral statements made regarding the subjects of this
More informationQ Supplement. August 6, 2014
Q2 2014 Supplement August 6, 2014 Disclaimer Please note that in this presentation, we may discuss events or results that have not yet occurred or been realized, commonly referred to as forward-looking
More informationWalgreens Boots Alliance 3Q16 Consolidated Financial Results Earnings conference call. 6 July 2016
Walgreens Boots Alliance 3Q16 Consolidated Financial Results Earnings conference call 6 July 2016 Agenda Topic Introduction & safe harbor Opening remarks Financial review Questions & answers Speaker Gerald
More informationQ Earnings. October 28, 2015
Q4 2015 Earnings October 28, 2015 Forward-Looking Statements and Non-GAAP Measures Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the U.S.
More informationKey Performance Indicators & Non-GAAP Measures
Key Performance Indicators & Non-GAAP Measures Management reviews a variety of key performance indicators including revenue, segment operating income and margins, earnings per share, order growth, and
More informationFebruary 21, Conduent Q4 & FY 2017 Earnings Results
February 21, 2018 Conduent Q4 & FY 2017 Earnings Results Cautionary Statements Forward-Looking Statements This report contains forward-looking statements that involve risks and uncertainties. These statements
More informationORACLE CORPORATION. Q3 FISCAL 2019 FINANCIAL RESULTS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ($ in millions, except per share data)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ($ in millions, except per share data) % Increase Three Months Ended February 28, % Increase (Decrease) % of % of (Decrease) in Constant 2019 Revenues 2018
More informationVISTEON CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in Millions, Except Per Share Data) (Unaudited)
VISTEON CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in Millions, Except Per Share Data) (Unaudited) 2018 2017 Sales $ 814 $ 810 Cost of sales (685) (681) Gross margin 129
More information4Q 2017 Highlights and Operating Results
4Q 2017 Highlights and Operating Results January 30, 2018 1 4Q 2017 Highlights and Operating Results Table of Contents Page(s) 1 Sales Overview 4-8 2 Financial Performance Trends 9-16 3 Leverage Metrics
More informationQ3 Fiscal Year 2013 Earnings Conference Call
NASDAQ: CMCO Q3 Fiscal Year 2013 Earnings Conference Call January 25, 2013 Timothy T. Tevens President & Chief Executive Officer Gregory P. Rustowicz Vice President - Finance & Chief Financial Officer
More informationMSCI. Raymond James 38 th Annual Institutional Investors Conference. Kathleen Winters, CFO. March 8, 2017
MSCI Raymond James 38 th Annual Institutional Investors Conference Kathleen Winters, CFO March 8, 2017 2017 MSCI Inc. All rights reserved. Please refer to the disclaimer at the end of this document. FORWARD
More informationKey Performance Indicators & Non-GAAP Measures
Key Performance Indicators & Non-GAAP Measures Management reviews a variety of key performance indicators including revenue, segment operating income and margins, earnings per share, order growth, and
More informationECOLAB FIRST QUARTER 2018
1Q 2018 Overview Sales: ECOLAB FIRST QUARTER 2018 Reported sales +10% and fixed currency and acquisition adjusted fixed currency sales +6%. New business growth, share gains, pricing and new product introductions
More informationQ2 Fiscal 2016 Earnings Presentation August 2, endurance.com /
Q2 Fiscal 2016 Earnings Presentation August 2, 2016 FORWARD LOOKING STATEMENTS AND OTHER IMPORTANT CAUTIONS This presentation contains certain forward-looking statements within the meaning of the Private
More informationFourth Quarter and FY 2017 Earnings Presentation November 29, 2017
Fourth Quarter and FY 2017 Earnings Presentation November 29, 2017 Cautionary statements This presentation contains forward-looking statements that are subject to known and unknown risks and uncertainties,
More informationEarnings Call Presentation. 3 rd Quarter 2015 October 29, 2015
Earnings Call Presentation 3 rd Quarter 2015 October 29, 2015 Safe Harbor Statement Our disclosures in this presentation, including without limitation, those relating to future financial results guidance
More informationCushman & Wakefield. Q3 Earnings Presentation November 13, 2018
Cushman & Wakefield Q3 Earnings Presentation November 13, 2018 Cautionary Note on Forward-Looking Statements All statements in this presentation (and oral statements made regarding the subjects of this
More informationMay 9, First Quarter 2018 Results
May 9, 2018 First Quarter 2018 Results Forward-looking statements This presentation, as well as other statements made by Delphi Technologies PLC (the Company ), contain forward-looking statements that
More informationKraton Corporation. First Quarter 2018 Earnings Presentation. April 26, 2018
Kraton Corporation First Quarter 2018 Earnings Presentation April 26, 2018 Disclaimers Forward Looking Statements Some of the statements and information in this presentation contain forward-looking statements
More informationTI Fluid Systems plc Results Presentation for TI Fluid Systems plc 20 March 2018
2017 Results Presentation for 20 March 2018 Disclaimer This presentation contains certain forward-looking statements with respect to the financial condition, results of operations and business of (the
More informationPTC PREPARED REMARKS FOURTH QUARTER AND FULL YEAR FISCAL 2017 OCTOBER 25, 2017
PTC PREPARED REMARKS FOURTH QUARTER AND FULL YEAR FISCAL 2017 OCTOBER 25, 2017 Please refer to the Important Disclosures section of these prepared remarks for important information about our operating
More informationNew Revenue Rules ASC 606. September 5, 2017
New Revenue Rules ASC 606 September 5, 2017 2 Welcome Safe Harbor Non-GAAP Financial Measures and Other Key Performance Measures To supplement our condensed consolidated financial statements, which are
More information4Q 2018 Highlights and Operating Results. Products. Technology. Services. Delivered Globally.
4Q 2018 Highlights and Operating Results Products. Technology. Services. Delivered Globally. Table of Contents Page 3 Safe Harbor Statement and Non-GAAP Financial Measures 4 Sales Overview 9 Overview of
More informationFourth Quarter and FY 2018 Earnings Presentation November 28, 2018
Fourth Quarter and FY 2018 Earnings Presentation November 28, 2018 Cautionary statements This presentation contains forward-looking statements that are subject to known and unknown risks and uncertainties,
More informationFiscal 2019 First Quarter Results. December 20, 2018
Fiscal 2019 First Quarter Results December 20, 2018 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are
More informationSecond Quarter 2017 Earnings Call
Second Quarter 2017 Earnings Call July 27, 2017 Nick Zarcone President & Chief Executive Officer & Chief Financial Officer Michael Clark Vice President- Finance and Controller Joe Boutross Director, Investor
More informationCRANE CO. Q EARNINGS RELEASE CALL
CRANE CO. Q1 2015 EARNINGS RELEASE CALL Forward-Looking Statements - Disclaimer The information in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation
More informationECOLAB THIRD QUARTER 2018
3Q 2018 Overview Sales: ECOLAB THIRD QUARTER 2018 Reported sales +5%; fixed currency sales were +6%, with acquisition adjusted fixed currency sales +7%. New business growth, share gains, pricing and new
More information